127 related articles for article (PubMed ID: 15309202)
41. Early prognostic usefulness of C-reactive protein added to the Thrombolysis In Myocardial Infarction risk score in acute coronary syndromes.
Foussas SG; Zairis MN; Lyras AG; Patsourakos NG; Tsirimpis VG; Katsaros K; Beldekos DJ; Handanis SM; Mytas DZ; Karidis KS; Tselioti PG; Prekates AA; Ambrose JA
Am J Cardiol; 2005 Aug; 96(4):533-7. PubMed ID: 16098307
[TBL] [Abstract][Full Text] [Related]
42. Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study.
Bellocci F; Biasucci LM; Gensini GF; Padeletti L; Raviele A; Santini M; Giubilato G; Landolina M; Biondi-Zoccai G; Raciti G; Sassara M; Castro A; Kheir A; Crea F
J Cardiovasc Med (Hagerstown); 2007 Apr; 8(4):293-9. PubMed ID: 17413310
[TBL] [Abstract][Full Text] [Related]
43. Preventive cardiology: move over low density lipoprotein cholesterol, hello C-reactive protein?
Genest J
Can J Cardiol; 2004 Aug; 20 Suppl B():89B-92B. PubMed ID: 15309211
[TBL] [Abstract][Full Text] [Related]
44. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study.
Morange PE; Bickel C; Nicaud V; Schnabel R; Rupprecht HJ; Peetz D; Lackner KJ; Cambien F; Blankenberg S; Tiret L;
Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2793-9. PubMed ID: 17023678
[TBL] [Abstract][Full Text] [Related]
45. [Inflammatory markers and cytokines in cardiovascular disease].
Ogiwara F; Takahashi M; Ikeda U
Rinsho Byori; 2004 Aug; 52(8):686-92. PubMed ID: 15478624
[TBL] [Abstract][Full Text] [Related]
46. Relationship between endogenous testosterone and cardiovascular risk in early postmenopausal women.
Maturana MA; Breda V; Lhullier F; Spritzer PM
Metabolism; 2008 Jul; 57(7):961-5. PubMed ID: 18555838
[TBL] [Abstract][Full Text] [Related]
47. Comparison of differing C-reactive protein assay methods and their impact on cardiovascular risk assessment.
Clarke JL; Anderson JL; Carlquist JF; Roberts RF; Horne BD; Bair TL; Kolek MJ; Mower CP; Crane AM; Roberts WL; Muhlestein JB;
Am J Cardiol; 2005 Jan; 95(1):155-8. PubMed ID: 15619419
[TBL] [Abstract][Full Text] [Related]
48. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study.
Tzoulaki I; Murray GD; Lee AJ; Rumley A; Lowe GD; Fowkes FG
Circulation; 2005 Aug; 112(7):976-83. PubMed ID: 16087797
[TBL] [Abstract][Full Text] [Related]
49. C-reactive protein gene polymorphisms, C-reactive protein blood levels, and cardiovascular disease risk.
Hage FG; Szalai AJ
J Am Coll Cardiol; 2007 Sep; 50(12):1115-22. PubMed ID: 17868801
[TBL] [Abstract][Full Text] [Related]
50. Prognostic significance of the admission plasma B-type natriuretic peptide measurement in patients with first ST-elevation myocardial infarction in comparison with C-reactive protein and TIMI risk score.
Kuklinska AM; Sobkowicz B; Mroczko B; Sawicki R; Musial WJ; Knapp M; Dobrzycki S; Szmitkowski M
Clin Chim Acta; 2007 Jul; 382(1-2):106-11. PubMed ID: 17482153
[TBL] [Abstract][Full Text] [Related]
51. C-reactive protein in atherosclerosis: A causal factor?
Paffen E; DeMaat MP
Cardiovasc Res; 2006 Jul; 71(1):30-9. PubMed ID: 16624260
[TBL] [Abstract][Full Text] [Related]
52. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects.
Anand DV; Lahiri A; Lim E; Hopkins D; Corder R
J Am Coll Cardiol; 2006 May; 47(9):1850-7. PubMed ID: 16682312
[TBL] [Abstract][Full Text] [Related]
53. Interleukin-10 (IL-10): an update on its relevance for cardiovascular risk.
Girndt M; Kohler H
Nephrol Dial Transplant; 2003 Oct; 18(10):1976-9. PubMed ID: 13679468
[No Abstract] [Full Text] [Related]
54. Cardiovascular disease. Does inflammation cut to the heart of the matter?
Taubes G
Science; 2002 Apr; 296(5566):242-5. PubMed ID: 11951014
[No Abstract] [Full Text] [Related]
55. Possible mechanisms of C-reactive protein mediated acute myocardial infarction.
Fordjour PA; Wang Y; Shi Y; Agyemang K; Akinyi M; Zhang Q; Fan G
Eur J Pharmacol; 2015 Aug; 760():72-80. PubMed ID: 25895642
[TBL] [Abstract][Full Text] [Related]
56. C-reactive protein for risk assessment in coronary artery disease.
Danchin N
Heart; 2010 Mar; 96(5):325-7. PubMed ID: 19933748
[No Abstract] [Full Text] [Related]
57. [C-reactive protein--marker of inflammation in atherosclerosis (new data)].
Nasonov EL; Paniukova EV; Aleksandrova EN
Kardiologiia; 2002; 42(7):53-62. PubMed ID: 12494114
[TBL] [Abstract][Full Text] [Related]
58. [Extended risk assessment in persons at risk of myocardial infarction: quantification of atherosclerosis or inflammation?].
Möhlenkamp S; Erbel R
MMW Fortschr Med; 2010 Apr; 152(14):39-41, 43. PubMed ID: 20614746
[No Abstract] [Full Text] [Related]
59. Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction.
Anderson TJ
Heart Fail Rev; 2003 Jan; 8(1):71-86. PubMed ID: 12652161
[TBL] [Abstract][Full Text] [Related]
60. Mayo Clinic office visit. Testing C-reactive protein. An interview with Thomas Behrenbeck, M.D., Ph.D.
Behrenbeck T
Mayo Clin Womens Healthsource; 2010 Feb; 14(2):6. PubMed ID: 20048728
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
